1. Home
  2. LOBO vs MEIP Comparison

LOBO vs MEIP Comparison

Compare LOBO & MEIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LOBO
  • MEIP
  • Stock Information
  • Founded
  • LOBO 2014
  • MEIP 2000
  • Country
  • LOBO China
  • MEIP United States
  • Employees
  • LOBO N/A
  • MEIP N/A
  • Industry
  • LOBO
  • MEIP Biotechnology: Pharmaceutical Preparations
  • Sector
  • LOBO
  • MEIP Health Care
  • Exchange
  • LOBO NYSE
  • MEIP Nasdaq
  • Market Cap
  • LOBO 16.3M
  • MEIP 16.3M
  • IPO Year
  • LOBO 2024
  • MEIP 2003
  • Fundamental
  • Price
  • LOBO $1.79
  • MEIP $2.87
  • Analyst Decision
  • LOBO
  • MEIP Hold
  • Analyst Count
  • LOBO 0
  • MEIP 2
  • Target Price
  • LOBO N/A
  • MEIP $7.00
  • AVG Volume (30 Days)
  • LOBO 14.9K
  • MEIP 36.2K
  • Earning Date
  • LOBO 09-30-2024
  • MEIP 02-11-2025
  • Dividend Yield
  • LOBO N/A
  • MEIP N/A
  • EPS Growth
  • LOBO N/A
  • MEIP N/A
  • EPS
  • LOBO 0.00
  • MEIP N/A
  • Revenue
  • LOBO $19,469,766.00
  • MEIP N/A
  • Revenue This Year
  • LOBO $72.16
  • MEIP N/A
  • Revenue Next Year
  • LOBO $41.04
  • MEIP $300.00
  • P/E Ratio
  • LOBO $1,496.48
  • MEIP N/A
  • Revenue Growth
  • LOBO N/A
  • MEIP 33.76
  • 52 Week Low
  • LOBO $1.35
  • MEIP $2.30
  • 52 Week High
  • LOBO $4.70
  • MEIP $4.97
  • Technical
  • Relative Strength Index (RSI)
  • LOBO N/A
  • MEIP 66.22
  • Support Level
  • LOBO N/A
  • MEIP $2.56
  • Resistance Level
  • LOBO N/A
  • MEIP $2.78
  • Average True Range (ATR)
  • LOBO 0.00
  • MEIP 0.15
  • MACD
  • LOBO 0.00
  • MEIP 0.04
  • Stochastic Oscillator
  • LOBO 0.00
  • MEIP 100.00

About LOBO LOBO EV TECHNOLOGIES LTD

Lobo EV Technologies Ltd is an electric vehicle manufacturer and seller company. It designs, develops, manufactures, and sells e-bicycles, e-mopeds, e-tricycles, and electric off-highway four-wheeled shuttles such as golf carts and mobility scooters for the elderly and disabled persons, also provides automobile information and entertainment software development and design services to customers. The company operates in two operating segments: Electric vehicles and accessories sales which generates key revenue, and software royalties and development and design services. It generates all of its revenue within the People's Republic of China.

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Share on Social Networks: